oncolyt
herp
simplex
virus
hsv
clinic
trial
treatment
malign
glioma
assum
select
tumor
cell
replic
strongli
attenu
quiescent
cell
cycl
cell
oncolyt
select
thought
occur
mutat
viral
encod
viral
ribonucleotid
reductas
function
andor
function
respect
complement
mammalian
ribonucleotid
reductas
whose
gene
express
cycl
cell
howev
estim
malign
glioma
cell
mitosi
one
time
therefor
effect
replic
hsv
oncolyt
virus
might
limit
subpopul
tumor
cell
sinc
one
time
major
tumor
cell
would
cycl
howev
report
hsv
defect
function
replic
quiescent
cultur
murin
embryon
fibroblast
obtain
mice
homozyg
delet
furthermor
intracrani
inocul
viru
brain
mice
provid
evid
viral
replic
occur
viru
inject
brain
wildtyp
mice
approach
provid
vitro
vivo
evid
hsv
molecularli
target
replic
quiescent
tumor
cell
carri
specif
oncogen
delet
independ
cell
cycl
statu
oncolyt
herp
simplex
virus
hsv
clinic
trial
treatment
malign
glioma
assum
select
tumor
cell
replic
strongli
attenu
quiescent
cell
cycl
cell
oncolyt
select
thought
occur
mutat
viral
encod
viral
ribonucleotid
reductas
function
andor
function
respect
complement
mammalian
ribonucleotid
reductas
whose
gene
express
cycl
cell
howev
estim
malign
glioma
cell
mitosi
one
time
therefor
effect
replic
hsv
oncolyt
virus
might
limit
subpopul
tumor
cell
sinc
one
time
major
tumor
cell
would
cycl
howev
report
hsv
defect
function
replic
quiescent
cultur
murin
embryon
fibroblast
obtain
mice
homozyg
delet
furthermor
intracrani
inocul
viru
brain
mice
provid
evid
viral
replic
occur
viru
inject
brain
wildtyp
mice
approach
provid
vitro
vivo
evid
hsv
molecularli
target
replic
quiescent
tumor
cell
carri
specif
oncogen
delet
independ
cell
cycl
statu
oncogen
publish
onlin
march
keyword
oncolyt
viru
gene
therapi
glioma
brain
tumor
mechan
replic
tumorsuppressor
gene
oncolyt
herp
simplex
virus
hsv
undergon
extens
laboratori
investig
kirn
et
al
earli
clinic
trial
aghi
martuza
anticanc
agent
oncolyt
hsv
undergon
clinic
trial
mutat
hsv
gene
andor
encod
viral
ribonucleotid
reductas
vrr
function
allow
replic
wildtyp
hsv
occur
even
quiescent
cell
neuron
infect
enceph
caus
wildtyp
hsv
type
goldstein
weller
without
function
hsv
replic
sever
curtail
quiescent
cell
goldstein
weller
howev
cycl
cell
upregul
express
sphase
specif
gene
mrr
nucleic
acid
metabol
complement
defect
viral
function
thu
allow
mutant
hsv
replic
goldstein
weller
complement
provid
biolog
rational
employ
hsv
oncolyt
therapi
rational
base
preferenti
replic
cycl
versu
quiescent
cell
howev
oncolyt
hsv
target
glioma
cell
replic
moment
time
hoshino
et
al
major
glioma
cell
evad
oncolyt
hsv
therapi
particularli
oncolyt
hsv
administ
intratumor
rare
sphase
specif
treatment
like
radiat
chemotherapi
administ
daili
extend
period
time
allow
target
cell
might
enter
cell
cycl
later
cours
treatment
know
downstream
effect
hereaft
term
tumor
suppressor
gene
human
chromosom
delet
glioblastoma
kamiryo
et
al
prevent
transcript
factor
transcrib
sphase
gene
mrr
elledg
et
al
hypothes
mutat
would
complement
hsv
replic
even
cell
quiescenc
activ
cycl
therebi
enabl
hsv
overcom
limit
infect
quiescent
cell
molecularli
target
fashion
yield
infecti
determin
cultur
human
glioma
fibroblast
cell
cycl
well
quiescent
popul
cell
type
g
isol
fluoresc
activ
cell
sort
fac
overal
cell
produc
significantli
fibroblast
regardless
cell
cycl
statu
interestingli
ratio
yield
cycl
versu
noncycl
cell
nearli
threefold
higher
normal
fibroblast
glioma
cell
figur
suggest
cellular
machineri
quiescent
glioma
cell
complement
replic
higher
degre
quiescent
fibroblast
glioma
cell
possess
mutat
wang
et
al
investig
role
two
mutat
viral
replic
cultur
g
cell
experi
repeat
cycl
g
glioma
cell
express
wildtyp
possess
homozyg
delet
wang
et
al
ratio
yield
cyclingtog
glioma
cell
nearli
ident
cyclingtog
glioma
cell
figur
find
suggest
mutat
necessari
support
replic
arrest
tumor
cell
agreement
previou
find
cycl
tumor
cell
yoon
et
al
hand
experi
repeat
glioma
cell
figur
replic
greater
arrest
cell
arrest
cell
recoveri
plaqu
form
unit
pfu
ml
infecti
kosderiv
vrr
lacz
weller
univers
connecticut
farmington
ct
usa
goldstein
weller
h
infect
multipl
infect
moi
cultur
human
glioma
hf
human
fibroblast
glioma
glioma
cell
obtain
american
type
cultur
collectionatcc
manassa
va
usa
murin
mef
murin
embryon
fibroblast
obtain
r
depinho
dan
farber
cancer
institut
boston
usa
cell
either
cycl
g
g
isol
flow
cytometri
cell
maintain
dulbecco
modifi
eagl
medium
dmem
supplement
fetal
calf
serum
mm
glutamin
u
ml
penicillin
mg
ml
streptomycin
co
gener
lipofectamin
invitrogen
carlsbad
ca
usa
transfect
neomycin
resist
genecontain
plasmid
invitrogen
cdna
subunit
mrr
subclon
plasmid
subunit
mrr
cdna
gener
rtpcr
mrna
obtain
cell
use
primer
posit
subunit
code
sequenc
includ
aug
site
atccggatccac
primer
posit
includ
uaa
site
gcttaagcttatt
result
pcr
product
first
clone
ta
clone
vector
invitrogen
mef
isol
describ
sharpless
et
al
fac
analysi
cell
trypsin
centrifug
g
min
fix
gradual
addit
ice
cold
ethanol
min
wash
phosphat
buffer
salin
pb
cell
treat
rnase
mg
ml
min
wash
pb
resuspend
stain
ml
mm
propidium
iodid
mm
sodium
citrat
min
room
temperatur
cell
cycl
phase
distribut
determin
analyt
dna
flow
cytometri
describ
graybablin
et
al
altern
isol
g
g
cell
dna
content
cell
trypsin
resuspend
pb
fluoresc
activ
cell
sort
fac
sort
measur
viral
yield
cell
plate
plate
dmem
plu
fetal
calf
serum
next
day
cell
infect
moi
h
infect
cell
scrape
medium
subject
three
freezethaw
cycl
viru
titer
determin
plaqu
assay
vero
cell
standard
deviat
shown
b
ratio
viral
yield
cycl
cell
viral
yield
g
g
cell
six
differ
cell
line
analys
express
cell
hf
mef
mef
exhibit
significantli
greater
ratio
delet
counterpart
hf
mef
mef
mef
similar
result
shown
obtain
murin
fetal
astrocyt
phenotyp
obtain
r
depinho
cell
g
obtain
treat
mm
lovastatin
merck
rathway
nj
usa
h
lovastatin
convert
activ
form
describ
previous
graybablin
et
al
komata
et
al
ratio
yield
cyclingtog
cell
higher
human
fibroblast
higher
glioma
cell
figur
find
rais
possibl
mutat
might
contribut
support
replic
seen
quiescent
glioma
cell
glioma
tumor
cell
possess
mutat
also
varieti
genet
mutat
could
affect
viral
cellular
replic
farassati
et
al
smith
et
al
yield
determin
cycl
facsisol
g
murin
embryon
fibroblast
mef
fetal
astrocyt
wildtyp
well
transgen
mice
homozyg
delet
mef
fetal
astrocyt
support
replic
even
g
wherea
viral
replic
maintain
g
wildtyp
mef
fetal
astrocyt
figur
compar
result
obtain
pharmacolog
agent
lovastatin
use
induc
growth
arrest
data
shown
find
indic
delet
support
product
replic
hsv
quiescent
cell
confirm
loss
function
would
result
higher
level
mammalian
ribonucleotid
reductas
mrr
gene
express
regardless
cell
cycl
statu
elledg
et
al
measur
mrna
level
subunit
mrr
cycl
rel
noncycl
cell
use
realtim
revers
transcript
rt
pcr
cell
mef
ratio
mrr
subunit
mrna
cycl
rel
noncycl
cell
howev
cell
wildtyp
mef
human
fibroblast
mef
ratio
much
higher
figur
find
decreas
mrr
express
noncycl
cell
agre
publish
data
show
mrr
express
cycl
cell
expect
downregul
g
growtharrest
cell
elledg
et
al
howev
cell
mrr
express
maintain
g
regardless
cellcycl
statu
agreement
mechan
suppress
mrr
transcript
elledg
et
al
stabli
transfect
glioma
cell
overexpress
subunit
mrr
creat
cell
line
express
mrr
subunit
mrna
data
shown
infect
ratio
viral
yield
cycl
rel
noncycl
compar
seen
cell
nearli
threefold
lower
cell
figur
suggest
stabli
elev
mrr
subunit
express
throughout
cell
cycl
cell
figur
enabl
support
viral
replic
independ
cell
cycl
statu
manner
compar
seen
cell
figur
determin
effect
delet
replic
g
cell
vivo
studi
replic
toxic
ko
wildtyp
deriv
intracerebr
inocul
wildtyp
knockout
mice
cerebr
viral
titer
similar
wildtyp
hsv
inocul
brain
wildtyp
mice
howev
mice
produc
three
order
magnitud
wildtyp
mice
intracerebr
inocul
figur
viral
dose
kill
inocul
mice
day
inocul
two
order
magnitud
less
inocul
brain
mice
compar
wildtyp
mice
significantli
differ
wildtyp
hsv
inocul
brain
wildtyp
mice
figur
final
anatom
distribut
gene
express
neuron
much
greater
brain
mice
brain
wildtyp
mice
former
also
exhibit
evid
increas
inflammatori
necrot
effect
caus
host
immun
respons
like
aros
due
signific
viral
replic
treatment
group
figur
taken
togeth
find
confirm
valid
hypothesi
retain
signific
replic
abil
cell
defect
even
cell
postmitot
growth
arrest
oncolyt
virus
engin
hsv
produc
signific
anticanc
effect
preclin
aghi
martuza
specul
reason
lack
efficaci
includ
viral
dose
less
maximum
toler
dose
mutat
render
oncolyt
hsv
less
potent
ineffici
spatial
tempor
distribut
viru
wein
et
al
antihsv
immun
imped
viral
replic
ikeda
et
al
anoth
reason
limit
efficaci
assum
oncolyt
hsv
infect
lyse
cell
tumor
activ
divid
quiescent
tumor
cell
may
support
viral
replic
case
glioma
tumor
cell
may
activ
cycl
one
time
hoshino
et
al
quiescent
tumor
cell
support
oncolyt
hsv
replic
oncolyt
hsv
would
unabl
treat
tumor
like
glioma
larg
noncycl
fraction
particularli
oncolyt
virus
administ
intratumor
surgeri
unlik
sphase
specif
adjuv
treatment
chemotherapi
radiat
administ
daili
enabl
target
cell
enter
cell
cycl
differ
point
time
howev
result
indic
noncycl
cell
still
support
replic
hsv
find
impli
oncolyt
hsv
repres
molecularli
target
therapi
tumor
defect
tumor
suppressor
pathway
also
impli
type
herp
virus
poxvirus
vaccinia
viru
mccart
et
al
genet
defect
vrr
viral
thymidin
kinas
whose
cellular
ortholog
mammalian
thymidin
kinas
also
transcript
control
tumor
suppressor
pathway
may
also
replic
quiescent
cell
defect
pathway
figur
exhibit
greater
replic
brain
transgen
mice
brain
wildtyp
mice
plaqu
form
unit
pfu
per
gram
brain
tissu
recov
day
intracrani
inocul
wildtyp
fvb
jackson
laboratori
bar
harbor
usa
fvbderiv
mice
provid
r
depinho
wildtyp
ko
obtain
knipe
harvard
medic
school
boston
usa
virus
viral
recoveri
nearli
lower
inocul
brain
fvb
mice
three
experiment
group
student
ttest
mice
n
per
treatment
group
anesthet
ketaminexylazin
mg
kg
intraperiton
immobil
stereotact
apparatu
midlin
sagitt
incis
mm
skull
burr
hole
drill
l
mm
anterior
mm
right
bregma
ko
viru
pfu
ml
viru
buffer
mm
nacl
mm
tri
ph
inject
mm
dura
use
hamilton
syring
mice
euthan
becam
letharg
anorex
dehydr
distress
brain
cut
small
piec
suspend
volum
pb
twice
tumor
volum
homogen
manual
sonic
centrifug
g
min
supernat
isol
freez
thaw
three
time
viral
yield
determin
plaqu
assay
vero
cell
describ
standard
deviat
shown
b
viral
dose
pfu
requir
death
mice
day
intracrani
inocul
nearli
higher
inocul
fvb
mice
three
experiment
group
viru
mous
strain
combin
calcul
follow
portion
mice
surviv
day
inocul
viral
dose
fvb
mice
pfu
calcul
finney
probit
analysi
method
use
calcul
four
data
point
finney
c
posit
neuron
determin
stain
marker
gene
bgalactosidas
far
greater
signific
associ
necrosi
surround
inflammatori
infiltr
brain
mice
upper
panel
brain
wildtyp
fvb
mice
lower
panel
magnif
brain
frozen
liquid
nitrogencool
nmethylbutan
section
coron
cryostat
mm
thick
slide
underw
block
endogen
peroxidas
dako
pap
kit
dako
copenhagen
denmark
incub
goat
serum
min
reduc
nonspecif
background
stain
incub
mouseantibgalactosidas
antibodi
promega
bioscienc
madison
wi
usa
overnight
incub
rabbit
antimous
peroxidas
conjug
secondari
antibodi
dako
h
incub
deaminobenzidin
tetrahydrochlorid
per
protocol
dako
hematoxylin
stain
scale
bar
repres
mm
anoth
type
target
downstream
effector
repres
adenovirus
jiang
et
al
addit
virus
coronaviru
wurding
et
al
measl
viru
nakamura
et
al
engin
select
taken
cell
express
cell
surfac
receptor
mutant
epiderm
growth
factor
receptor
specif
found
tumor
virus
target
cell
alter
ra
mitogen
pathway
exampl
virus
includ
reoviru
norman
et
al
delet
viral
gene
fu
et
al
delet
viral
gene
smith
et
al
virus
target
tumor
cell
propens
exhibit
alter
biochem
properti
vesicular
stomat
viru
target
cell
alter
interferon
respons
stojdl
et
al
adenoviru
target
cell
shut
cellular
protein
synthesi
infect
oshea
et
al
one
key
distinct
type
target
found
hsv
lack
target
virus
target
hsv
lack
allow
infect
quiescent
tumor
cell
carri
delet
repres
cell
glioma
given
moment
time
hoshino
et
al
experiment
approach
compar
mef
mice
mef
wildtyp
mice
valid
hypothesi
hsv
target
nonrepl
cell
delet
superior
approach
employ
tumor
cell
without
appar
intact
gene
loci
tumor
cell
possess
mani
genet
mutat
may
also
affect
viral
replic
farassati
et
al
smith
et
al
even
tumor
cell
appear
intact
gene
loci
may
gene
inactiv
promot
methyl
andor
inactiv
compon
tumor
suppressor
pathway
costello
et
al
ono
et
al
ueki
et
al
burn
et
al
nakamura
et
al
watanab
et
al
ohgaki
kleihu
clinic
trial
continu
carri
oncolyt
virus
import
determin
retrospect
prospect
enhanc
viral
replic
patient
whose
tumor
carri
particular
mutat
known
complement
viral
defect
trial
determin
statu
tumor
suppressor
pathway
treat
tumor
may
crucial
order
identifi
patient
tumor
sensit
agent
